- Home
- PSHG vs ELUT Comparison
PSHG vs ELUT Comparison
Compare PSHG & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- ELUT
- Stock Information
- Founded
- PSHG 2010
- ELUT 2015
- Country
- PSHG Greece
- ELUT United States
- Employees
- PSHG N/A
- ELUT N/A
- Industry
- PSHG Marine Transportation
- ELUT Medical Specialities
- Sector
- PSHG Consumer Discretionary
- ELUT Health Care
- Exchange
- PSHG Nasdaq
- ELUT Nasdaq
- Market Cap
- PSHG 26.9M
- ELUT 25.2M
- IPO Year
- PSHG N/A
- ELUT 2020
- Fundamental
- Price
- PSHG $2.05
- ELUT $0.68
- Analyst Decision
- PSHG
- ELUT Strong Buy
- Analyst Count
- PSHG 0
- ELUT 2
- Target Price
- PSHG N/A
- ELUT $7.00
- AVG Volume (30 Days)
- PSHG 132.9K
- ELUT 239.5K
- Earning Date
- PSHG 11-25-2025
- ELUT 11-06-2025
- Dividend Yield
- PSHG N/A
- ELUT N/A
- EPS Growth
- PSHG N/A
- ELUT N/A
- EPS
- PSHG 1.33
- ELUT N/A
- Revenue
- PSHG $79,691,000.00
- ELUT $21,746,000.00
- Revenue This Year
- PSHG N/A
- ELUT $1.90
- Revenue Next Year
- PSHG $17.95
- ELUT $6.37
- P/E Ratio
- PSHG $1.49
- ELUT N/A
- Revenue Growth
- PSHG N/A
- ELUT 24.08
- 52 Week Low
- PSHG $1.31
- ELUT $0.58
- 52 Week High
- PSHG $2.34
- ELUT $5.12
- Technical
- Relative Strength Index (RSI)
- PSHG 49.24
- ELUT 31.75
- Support Level
- PSHG $1.97
- ELUT $0.58
- Resistance Level
- PSHG $2.24
- ELUT $0.77
- Average True Range (ATR)
- PSHG 0.11
- ELUT 0.07
- MACD
- PSHG -0.02
- ELUT -0.01
- Stochastic Oscillator
- PSHG 38.89
- ELUT 25.14
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.